{"analyses":[{"ciLowerLimit":"0.288","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.073","estimateComment":"HR was obtained by unadjusted Cox's proportional hazard regression model stratified by age, ISS, prior lines of therapy. HR \\>1 was deemed to indicate quicker response time in Ixazomib + Dexamethasone arm over Pomalidomide + Dexamethasone arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.556"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.953","upperLimit":"2.037","value":"1.1"},{"groupId":"OG001","lowerLimit":"1.906","upperLimit":"2.858","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time to response was defined as the time from randomization to the first documentation of PR/VGPR/CR. Per IMWG criteria, PR: \\>=50% reduction of serum M protein + reduction in 24-hour urinary M protein by \\>=90% or to \\<200 mg/24-hour; if M-protein is not measurable, \\>=50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, \\>=50% reduction in bone marrow plasma cells, when Baseline value \\>=30% and; if present at Baseline, \\>=50% reduction in size of soft tissue plasmacytomas is required. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein + urine M-protein level \\<100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; \\<5% plasma cells in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"Response Evaluable Population included all participants with multiple myeloma who had documentation of a confirmed PR, or PR/VGPR/CR.","reportingStatus":"POSTED","timeFrame":"From date of randomization until first documentation of CR, VGPR or PR (Up to approximately 3 years)","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}